News

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
Innovation, inclusion, and urgency  define Kigali HIV conference ANALYSIS | RONALD MUSOKE | When the 13th International AIDS ...
Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
South Africa has the world’s largest HIV treatment programme, with over 5. 5 million people receiving antiretrovirals (ARVs).
WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...
Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said.
Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...